Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication ... Dec 22
The broad-spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being developed by ImmuneMed, is on track to progress as a treatment for the ... Dec 21
Opaganib demonstrated potent antiviral activity against SARS-CoV-2, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. ... Oct 22
-Advertisements-